The application discloses application of hnRNPL in preparation of
glioma diagnosis, treatment and prognosis evaluation products, and belongs to the technical field of biological
medicine. Through
bioinformatics and clinical sample
verification, it is confirmed that hnRNPL is significantly highly expressed in
glioma tissues, and the expression level thereof is negatively correlated with the total
survival period of patients, and hnRNPL has the function of promoting the occurrence and development of
glioma. Mechanism research shows that hnRNPL can be used as a key
alternative splicing factor, which promotes the skipping of the second
exon of SH3BGRL by combining with the CA-rich sequence on the SH3BGRL pre-mRNA, thereby generating functional SH3BGRL
protein, and driving the proliferation, migration and invasion of glioma cells. Based on this, hnRNPL can be used as a
molecular marker for the diagnosis and prognosis evaluation of glioma, and an inhibitor targeting hnRNPL can effectively inhibit the malignant progression of glioma.